Educational Reference Only Not medical advice. No sourcing, vendor, pricing, or compounding information provided. Consult a qualified healthcare provider.

Peptide Desk ReferencePDR
RecoveryGrey-marketEvidence: C

GHK-Cu

Also known as: Copper Peptide GHK, Glycyl-L-histidyl-L-lysine:copper(II)

Copper PeptideTissue RepairSkin HealthAnti-aging

Grey-Market Compound. This compound is not approved by the FDA or any major regulatory authority. No established regimen exists. Products available outside of regulated channels lack standardized manufacturing, quality control, and potency verification. Consult a qualified clinician. Research-only risks apply.

Overview

Clinical Summary

GHK-Cu is a naturally occurring copper-binding tripeptide (glycyl-histidyl-lysine) found in human plasma, saliva, and urine. Plasma levels decline with age. It has been studied for wound healing, skin remodeling, and anti-inflammatory properties. While it has a long history in cosmeceutical applications (topical creams and serums), injectable use is primarily a grey-market phenomenon with limited clinical data.

Plain Language Summary

GHK-Cu is a small peptide naturally present in your blood that binds to copper. It decreases as you age. Research suggests it plays a role in wound healing, collagen production, and skin repair. It is commonly found in anti-aging skincare products. Some people use injectable forms for broader anti-aging or recovery purposes, but clinical evidence for injectable use is limited.

Mechanism of Action

GHK-Cu chelates copper(II) ions, facilitating their delivery to tissues. The copper complex stimulates collagen synthesis, promotes decorin production (a proteoglycan involved in tissue architecture), increases VEGF expression for angiogenesis, and activates metalloproteinases for tissue remodeling. GHK-Cu has been shown to modulate gene expression of over 4,000 genes, with broad effects on antioxidant defense, anti-inflammatory pathways, DNA repair, and stem cell biology. It also promotes nerve growth factor synthesis.

Evidence Summary

Evidence Grade:Evidence: C

In vitro and animal studies demonstrate accelerated wound closure, increased collagen deposition, enhanced angiogenesis, and reduced inflammation. Human data are primarily from dermatological studies of topical application, showing improved skin elasticity, firmness, and wound healing in small trials. Gene expression studies (Pickart et al.) have characterized broad transcriptomic effects. No RCTs exist for systemic (injectable) administration in humans.

Safety Profile

Topical GHK-Cu has a good safety profile based on decades of cosmeceutical use. Injectable use has not been systematically evaluated for safety. Copper homeostasis disruption is a theoretical concern with systemic administration, though the low peptide doses typically used are unlikely to cause significant copper toxicity. No serious adverse events have been reported in published literature for any route of administration.

Contraindications

  • Wilson disease or other copper metabolism disorders
  • Known hypersensitivity
  • Pregnancy and breastfeeding (insufficient data for injectable use)

Adverse Events

  • Injection site irritation (anecdotal)
  • Skin flushing (rare, anecdotal)
  • No systematic adverse event data for injectable use

Interactions

  • Theoretical interaction with copper chelators (penicillamine, trientine)
  • No formal interaction studies for injectable use

Regulatory Notes

GHK-Cu is not FDA-approved as an injectable medication. It is widely available in cosmeceutical products (topical) without prescription. Injectable forms are sold as research chemicals in the grey market. No active clinical development programs for injectable GHK-Cu are publicly known.

Monitoring Considerations

For injectable use, clinicians may consider monitoring serum copper and ceruloplasmin levels, particularly with prolonged use. Monitor skin and tissue response to treatment.

These are general considerations for clinical awareness and do not constitute prescriptive monitoring recommendations for any individual patient.

Stability and Handling Notes

The copper-peptide complex is relatively stable in lyophilized form. Reconstituted solutions should be protected from light and stored refrigerated. Grey-market products lack standardized stability data.

References

  1. 1
    review

    The Human Tripeptide GHK-Cu in Prevention of Oxidative Stress and Degenerative Conditions of Aging

    Pickart L, Vasquez-Soltero JM, Margolina A. (2012). Oxidative Medicine and Cellular Longevity

    Key findings: GHK-Cu modulates expression of 4,000+ human genes. Suppresses fibrinogen synthesis, activates DNA repair genes, and increases antioxidant enzyme expression.

    Limitations: Primarily gene expression analysis; functional outcomes less established.

    View source
  2. 2
    review

    GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration

    Pickart L, Margolina A. (2018). BioMed Research International

    Key findings: Review of GHK-Cu effects on collagen synthesis, wound healing, anti-inflammatory activity, and skin remodeling.

    Limitations: Focused on topical/dermal applications; injectable data limited.

Last reviewed: 2024-10-20 | Version: 1 | Status: Published

More in Recovery

RecoveryGrey-marketEvidence: C

BPC-157

Body Protection Compound-157 · Bepecin · PL 14736 · PL-10

BPC-157 is a lab-made peptide based on a protein found naturally in stomach acid. In animal studies, it has shown remarkable healing properties for muscles, tendons, ligaments, the gut lining, and other tissues. However, there are very few human studies, so we do not know for certain whether these effects translate to people. It is popular among athletes and biohackers but is not an approved medication anywhere.

View monograph
RecoveryGrey-marketEvidence: C

TB-500

Thymosin Beta-4 · TB4 · Timbetasin

TB-500 is a synthetic form of thymosin beta-4, a natural peptide your body already makes. It plays a role in healing wounds and reducing inflammation. Animal studies show it can speed up healing of muscles, tendons, and skin. Some human studies exist for eye and skin wound healing, but there is limited clinical evidence for the musculoskeletal uses that make it popular. It is not an approved medication.

View monograph
RecoveryGrey-marketEvidence: C

KPV

Lys-Pro-Val · alpha-MSH(11-13) · alpha-MSH C-terminal tripeptide

KPV is a small fragment of a natural hormone called alpha-MSH that helps control inflammation in the body. Researchers are interested in it because animal studies suggest it can reduce gut inflammation and may help with skin conditions. It has not been tested in human clinical trials, so its safety and effectiveness in people are not established. It is currently available only through unregulated sources.

View monograph

Want to discuss this compound with a qualified physician?

The Peptide Association has verified over 160 licensed providers specializing in peptide therapy, with telehealth options available in most states.

Find a Verified Provider